tiprankstipranks
CytomX Therapeutics Inc (DE:6C1)
FRANKFURT:6C1

CytomX Therapeutics Stock Price & Analysis

0 Followers

6C1 Stock Chart & Stats

Day’s Range€0 - €0
52-Week Range― - ―
Previous Close€1.46
Volume0.00
Average Volume (3M)8.65K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)€228.16M
Total Debt (Recent Filing)€18.89M
P/E RatioN/A
Beta0.38
Next EarningsNov 08, 2022
EPS Estimate-€0.31
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)N/A
Shares Outstanding65,950,242
R-SquaredN/A
Standard DeviationN/A
10 Day Avg. Volume1,205
30 Day Avg. Volume8,646
P/B Ratio2.04
P/S Ratio1.76
P/CF Ratio10.30
P/FCF Ratio-0.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/EbitdaN/A
Price Target Upside181.86% Upside
Rating ConsensusModerate Buy
AlphaN/A
Number of Analyst Covering10


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

6C1 FAQ

What was CytomX Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is CytomX Therapeutics’s market cap?
Currently, no data Available
When is CytomX Therapeutics’s upcoming earnings report date?
CytomX Therapeutics’s upcoming earnings report date is Nov 08, 2022 which is in 35 days.
    How were CytomX Therapeutics’s earnings last quarter?
    CytomX Therapeutics released its earnings results on Aug 04, 2022. The company reported -€0.377 earnings per share for the quarter, beating the consensus estimate of -€0.38 by €0.003.
      Is CytomX Therapeutics overvalued?
      According to Wall Street analysts CytomX Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
        Does CytomX Therapeutics pay dividends?
        CytomX Therapeutics does not currently pay dividends.
        What is CytomX Therapeutics’s EPS estimate?
        CytomX Therapeutics’s EPS estimate is -€0.31.
          How many shares outstanding does CytomX Therapeutics have?
          Currently, no data Available
          What happened to CytomX Therapeutics’s price movement after its last earnings report?
          CytomX Therapeutics reported an EPS of -€0.377 in its last earnings report, beating expectations of -€0.38. Following the earnings report the stock price went up 0.502%.
            Which hedge fund is a major shareholder of CytomX Therapeutics?
            Among the largest hedge funds holding CytomX Therapeutics’s share is Platinum Investment Management. It holds CytomX Therapeutics’s shares valued at 2M.

              ---

              CytomX Therapeutics Stock Analysis

              Smart ScoreUnderperform
              1
              2
              3
              4
              5
              6
              7
              8
              9
              10
              2
              The CytomX Therapeutics Holdings stock analysis is based on the TipRanks Smart Score which is derived from 6 unique data sets including Analyst recommendations, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
              Learn more about TipRanks Smart Score

              Company Description

              CytomX Therapeutics Inc

              CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.

              ---
              Similar Stocks
              Company
              Price & Change
              Follow
              AbbVie
              Amgen
              Gilead Sciences
              Moderna
              Vertex Pharmaceuticals

              Popular Stocks

              ---
              What's Included in PREMIUM?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis